Nature Reviews Study Puts Global MetALD Prevalence at 4.1%, Warning Many Cases Are Missed
Updated
Updated · BIOENGINEER.ORG · Aug 18
Nature Reviews Study Puts Global MetALD Prevalence at 4.1%, Warning Many Cases Are Missed
2 articles · Updated · BIOENGINEER.ORG · Aug 18
Summary
About 4.1% of adults worldwide may have metabolic and alcohol-associated liver disease, a newly defined condition in which alcohol exposure overlaps with obesity, diabetes, hypertension or abnormal blood lipids.
Many cases are likely missed because routine care often undercaptures drinking patterns and early liver injury; the review says PEth blood testing can raise MetALD detection by as much as fourfold.
Compared with MASLD alone, MetALD appears more likely to progress to steatohepatitis, advanced fibrosis, cirrhosis, liver failure and hepatocellular carcinoma because alcohol and metabolic stress can act synergistically.
The authors back risk-based screening using non-invasive fibrosis tests and elastography for high-risk patients, with treatment combining alcohol reduction, weight loss, diabetes control and cardiovascular risk management.
Regional burdens vary with drinking, obesity and diabetes patterns, and the study calls the 4.1% figure a benchmark rather than a final count as definitions and measurement methods remain inconsistent.